GLP-1 drugs are usually discussed as weight-loss medications. But in India, the much bigger story may be diabetes, cardiovascular disease, kidney disease — and affordability. Semaglutide has now gone off patent in India, opening the door for lower-cost Indian…
About this episode
GLP-1 drugs are usually discussed as weight-loss medications. But in India, the much bigger story may be diabetes, cardiovascular disease, kidney disease — and affordability. Semaglutide has now gone off patent in India, opening the door for lower-cost Indian…
What to consider
This video is part of the API TO ROI research archive. Watch the original analysis for the presenter’s full context, evidence and conclusions.